(Q39486360)

12 September 2017

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial (English)

1 reference

12 September 2017

1 reference

Labrie F

1

1 reference

12 September 2017

Candas B

2

1 reference

12 September 2017

Dupont A

3

1 reference

12 September 2017

Cusan L

4

1 reference

12 September 2017

Gomez JL

5

1 reference

12 September 2017

Suburu RE

6

1 reference

12 September 2017

Diamond P

7

1 reference

12 September 2017

Lévesque J

8

1 reference

12 September 2017

Belanger A

9

1 reference

12 September 2017

1 February 1999

1 reference

12 September 2017

1 reference

12 September 2017

38

1 reference

12 September 2017

83-91

1 reference

12 September 2017

2

1 reference

12 September 2017

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

Should brachytherapy be considered a therapeutic option in localized prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

A New Test for 2 × 2 Tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

Cancer screening. Degrees of proof and practical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819990201%2938%3A2%3C83%3A%3AAID-PROS1%3E3.0.CO%3B2-B

10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference